The role of vasopressin in congestive heart failure

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.3, 2006, Pages

  Goldsmith, Steven R ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDIURETIC AGENT; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR;

BLOOD; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPONATREMIA; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; HEART FAILURE, CONGESTIVE; HUMANS; HYPONATREMIA; NEUROTRANSMITTER AGENTS; PROGNOSIS; RECEPTORS, VASOPRESSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33750592434     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_3.S19     Document Type: Article

References (40)

1. Goldsmith SR. Therapeutics in congestive heart failure: from hemodynamics to neurohormones. In: Singal PK; Dixon IMC; Kirshenbaum LA; Dhalla NS, eds. Cardiac Remodeling and Failure. Boston, MA: Kluwer Academic Publishers; 2003:17-34.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
5. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
6. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
8. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355.
9. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
10. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85:195-197.
11. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.
12. Francis GS, Goldsmith SR, Levine TB, et al. The neurohormonal axis in congestive heart failure. Ann Intern Med 1984; 101:370-377.
13. Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 1999; 5:347-356.
14. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146:9-18.
15. Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 1991; 69:239-245.
16. Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000; 391:39-48.
17. Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997; 99:1500-1505.
18. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305:263-266.
19. Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968; 32:745-759.
20. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1:1385-1390.
21. Goldsmith SR. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 2002; 8:251-256.
22. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
23. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24:583-591.
24. Stone CK, Imai N, Thomas A, et al. Hemodynamic effects of vasopressin inhibition in congestive heart failure. Clin Res 1986; 78:674-679.
25. Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J Clin Invest 1986; 78:674-679.
26. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994; 267:H2245-H2254.
27. Burrell LM, Phillips PA, Risvanis J, et al. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998; 275:H176-H182.
28. Mulinari RA, Gavras I, Wang YX, et al. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation 1990; 81:308-311.
29. Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 1996; 27:275-282.
30. Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med 1991; 117:313-318.
31. Clair MJ, King MK, Goldberg AT, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000; 293:852-860.
32. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287:860-867.
33. Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res 2002; 54:51-57.
34. Cowley AW Jr, Liard JF. Vasopressin and arterial pressure regulation. Special lecture. Hypertension 1988; 11:I25-I32.
35. Tabrizchi R, King K, Pang C. Vascular role of vasopressin in the presence and absence of influence from angiotensin II or alpha adrenergic system. Can J Physiol Pharmacol 1986; 64:1143-1148.
36. Goldsmith SR, Francis GS, Cowley AW, Goldenberg I, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986; 8:779-783.
37. Creager MA, Faxon DP, Cutler SS, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986; 7:758-765.
38. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690-2696.
39. Abraham WT, Oren RM, Crisman TS, et al. Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure. J Am Coll Cardiol 1997; 29(Suppl):169A. Abstract.
40. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 2004; 291:1963-1971.